Corridor Business Journal: University of Iowa Health Care announced today that it will be participating in a large, Phase 3 clinical trial for a new COVID-19 vaccine made by Novavax Inc. The multi-site clinical trial, which aims to enroll 30,000 participants, will further validate the safety, tolerability, immunogenicity and efficacy of the vaccine against COVID-19. The UI site started vaccinations on Jan. 4 and plans to enroll 250 participants.